Pancreatic Cancer Care Is Becoming Multimodal—Now It Needs to Become Integrated: The Lancet Gastroenterology & Hepatology | 2026

What Does This Commentary Highlight?

Modern PDAC management increasingly combines systemic therapy, surgery, molecular profiling and surveillance, but these components often remain disconnected.

Early systemic therapy is increasingly important, even in anatomically resectable PDAC.

PACT-21/CASSANDRA showed improved event-free survival with perioperative PAXG vs mFOLFIRINOX (16.0 vs 10.2 months).

The priority may be achieving adequate early systemic exposure, rather than rigidly separating neoadjuvant from adjuvant therapy.

Minimally invasive and vascular-resection techniques are expanding surgery in carefully selected patients.

Postoperative complications matter oncologically because they can delay or prevent subsequent chemotherapy.

At recurrence, selected patients may benefit from reconsideration of local as well as systemic treatment.

AI-pathology and emerging RAS-directed therapies could eventually enable more biologically informed treatment selection.

Why Does It Matter?

Every PDAC treatment decision influences what becomes possible later. Multidisciplinary care therefore needs to be longitudinal and adaptive, not simply a sequence of independent interventions.

GastroAGI Takeaway

The future of PDAC is not simply “more treatment”—it is better sequencing and integration. Diagnosis, early systemic therapy, surgery, recovery, pathology, surveillance and recurrence should form one continuous oncological strategy, repeatedly adapted to tumor biology and patient fitness.